Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrlalpathlabs

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Here are SP Tulsian's top trading ideas

      Here are SP Tulsian's top trading ideas

      In an interview to CNBC-TV18's Surabhi Upadhyay and Prashant Nair, SP Tulsian of sptulsian shared his views and outlook on the fundamentals of the market and specific stocks.

    • Buy Century Plyboards, Brigade Enterprises, HUDCO, Auro Pharma, Biocon: Gujral

      Buy Century Plyboards, Brigade Enterprises, HUDCO, Auro Pharma, Biocon: Gujral

      Ashwani Gujral of ashwanigujral.com suggests buying Century Plyboards, Brigade Enterprises, HUDCO, Aurobindo Pharma and Biocon.

    • Buy TVS Motor, Dr Lal PathLabs, Reliance Industrial Infrastructure: Ashwani Gujral

      Buy TVS Motor, Dr Lal PathLabs, Reliance Industrial Infrastructure: Ashwani Gujral

      Ashwani Gujral of ashwanigujral.com suggests buying TVS Motor Company, Dr Lal PathLabs and Reliance Industrial Infrastructure.

    • Buy, Sell, Hold: 8 stocks and 3 sectors are being tracked by analysts today

      Buy, Sell, Hold: 8 stocks and 3 sectors are being tracked by analysts today

      Persistent Systems, Bajaj Finance, NMDC and Titan, among others are on the radar of investors on Wednesday.

    • Buy, Sell, Hold: 4 stocks, 1 sector and 1 event are being tracked by analysts today

      Buy, Sell, Hold: 4 stocks, 1 sector and 1 event are being tracked by analysts today

      IT sector, GST rates as well as stocks such as Apollo Hospitals and United Spirits, among others, are on investors’ radar.

    • Nifty @10K likely on earnings growth surprise; these stocks can give >25% returns

      Nifty @10K likely on earnings growth surprise; these stocks can give >25% returns

      Earnings recovery and normal monsoon would be next key triggers for market, feel experts who expect that could drive the Nifty towards five digits mark (10,000).

    • Bull's Eye: Buy UBL, IGL, Vakrangee, Uflex; sell Godrej Ind

      Bull's Eye: Buy UBL, IGL, Vakrangee, Uflex; sell Godrej Ind

      Rakesh Bansal of RK Global is of the view that one may buy Vakrangee with a target of Rs 284.

    • Tulsian tells: Why he does not have a +ve take on liquor stocks

      Tulsian tells: Why he does not have a +ve take on liquor stocks

      In an interview with CNBC-TV18, market expert SP Tulsian listed his stock picks for the day and shared his market outlook.

    • CLSA's 6 midcap picks despite Nifty Midcap's 35% rise since Mar

      CLSA's 6 midcap picks despite Nifty Midcap's 35% rise since Mar

      The market has been partying hard since March on account of more than Rs 55,000 crore of FII inflows, the government's several initiatives to boost growth and US Fed holding off on a rate hike until now. The Midcap 100 index surged 35 percent, beating Nifty that jumped 25.65 percent since March 1.

    • Tulsian's take on market next week & tyre stocks, among others

      Tulsian's take on market next week & tyre stocks, among others

      In an interview to CNBC-TV18, SP Tulsian of sptulsian.com says he is cautious on markets for the next week due to onset of advance tax payment obligations which may lead to selling from domestic institutional investors.

    • CLSA retains buy on Dr Lal Path, volume growth to drive earnings

      CLSA retains buy on Dr Lal Path, volume growth to drive earnings

      Dr Lal derives 70 percent of its revenue from North India. The key to Dr Lal's business model is its hub and spoke model approach along with a strong over 1,500 patient service centre (PSC) network largely operated by franchisees.

    • Here are a few stock ideas from Ajay Bodke

      Here are a few stock ideas from Ajay Bodke

      In an interview to CNBC-TV18, Ajay Bodke, CEO & Chief Portfolio Manager (PMS) at Prabhudas Lilladher Pvt. Ltd shared his readings and outlook on market, specific stocks and sectors.

    • Ujjivan Financial Services looks attractive: Deepak Shenoy

      Ujjivan Financial Services looks attractive: Deepak Shenoy

      Deepak Shenoy of Capitalmind.in is of the view that Ujjivan Financial Services looks attractive.

    • Dr Lal PathLabs decent bet: Mehraboon Irani

      Dr Lal PathLabs decent bet: Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that Dr Lal PathLabs is a decent bet.

    • Buy Action Construction, Kaya, Praj Industries: Rakesh Bansal

      Buy Action Construction, Kaya, Praj Industries: Rakesh Bansal

      Rakesh Bansal of RK Global recommends buying Action Construction, Dr Lal Pathlabs, Kaya and Praj Industries.

    • Hold Dr Lal PathLabs, says Vijay Chopra

      Hold Dr Lal PathLabs, says Vijay Chopra

      Vijay Chopra of enochventures.com is of the view that one may hold Dr Lal PathLabs.

    • Look at Dr Lal PathLabs at lower levels: Sudip Bandopadhyay

      Look at Dr Lal PathLabs at lower levels: Sudip Bandopadhyay

      Sudip Bandopadhyay, Market Expert is of the view that one may look at Dr Lal PathLabs at lower levels.

    • Buy Alkem Laboratories, says SP Tulsian

      Buy Alkem Laboratories, says SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may Alkem Laboratories and one should book profits in Dr Lal Pathlab.

    • Nirmal Bang says hold Dr Lal for long-term, like Alkem too

      Nirmal Bang says hold Dr Lal for long-term, like Alkem too

      Runjhun Jain, Senior Research Analyst, Nirmal Bang is bullish on both Dr Lal Pathlabs and Alkem Laboratories.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347